Key Pharma & Biotech Predictions for 2016



Download Your Copy

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

Pharma IQ examined the market to pinpoint the forecasted trends for the market next year. After consulting the expertise of an array of industry specialists, Pharma & Cold Chain IQ presents itstop predicted trends for 2016.

In regards to the approaching year, Dr Steven Bradshaw European Director of Market Access Solutions noted: “2016 should be an interesting year in pharma. Some of the main items to watch are the effect of key biosimilar entries and the impact this will have, particularly in areas of diabetes and rheumatology, plus seeing how industry and payers will react in 2016 to approaching the pending launch of gamechanging medicines such as gene and cell therapies that have the potential to transform a large number of diseases, but will disrupt current paradigms of product evaluation and funding—an important issue that requires action because it won’t go away. 

“Additionally we are seeing value added services, particularly patient-focused offerings, being hot on the agenda for pharmaceutical companies, and real-world evidence (RWE) generation plans are now being introduced at an earlier stage in product development in markets where there is the infrastructure. HTA in Japan is still a pending process, but 2016 should provide more clues as to how this will be implemented.” 

To continue reading this story

Learn More   Existing Users